397 related articles for article (PubMed ID: 23916321)
1. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
[TBL] [Abstract][Full Text] [Related]
2. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
[TBL] [Abstract][Full Text] [Related]
3. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of state opioid substitution treatment program in Georgia.
Piralishvili G; Chavchanidze M; Gamkrelidze I; Nikolaishvili N
Georgian Med News; 2014 Apr; (229):62-6. PubMed ID: 24850608
[TBL] [Abstract][Full Text] [Related]
5. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
[TBL] [Abstract][Full Text] [Related]
6. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
7. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
[TBL] [Abstract][Full Text] [Related]
8. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
[TBL] [Abstract][Full Text] [Related]
11. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
12. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
13. Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.
Vijay A; Bazazi AR; Yee I; Kamarulzaman A; Altice FL
J Subst Abuse Treat; 2015 Jul; 54():29-36. PubMed ID: 25841703
[TBL] [Abstract][Full Text] [Related]
14. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
15. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.
Woody GE; Bruce D; Korthuis PT; Chhatre S; Poole S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Metzger D; Ling W
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):288-93. PubMed ID: 24751432
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
18. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
19. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
